Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott licenses 24 drugs from Zydos and forms an Established Products Division focused on emerging markets.

You may also be interested in...



Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy

NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21

Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy

NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21

Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy

Abbott will gain Piramal's branded generics unit, expected to generate more than $500 million in sales in 2011.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel